Get startedLog in
    Picture of ALX Oncology Holdings logo

    ALXO — ALX Oncology Holdings News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapMomentum Trap
    All News

    ALX Oncology Holdings Inc expected to post a loss of 46 cents a share - Earnings Preview

    Picture of ALX Oncology Holdings logoALX Oncology Holdings
    05/05/2025 12:26
    ALX Oncology Holdings Inc ALXO.OQ ALXO.O is expected to show no change in quarterly revenue when it reports  results on May 8 for the period ending March 31 2025

​LSEG's mean analyst estimate for ALX Oncology Holdings Inc is for a loss of 46 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for ALX Oncology Holdings Inc is $4.00​, above​ its last closing price of $0.53. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​


    QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATEACTUALBEAT, MET, MISSEDSURPRISE %
    Dec. 31 2024-0.62-0.67-0.55Beat17.9
    Sep. 30 2024-0.78-0.78-0.58Beat25.6
    Jun. 30 2024-0.77-0.77-0.76Beat1.7​
    Mar. 31 2024-0.85-0.84-0.71Beat15.1
    ​​Dec. 31 2023-0.81-0.84-0.93Missed-10.5
    Sep. 30 2023-0.82-0.87-1.24Missed-42.5​
    Jun. 30 2023-0.88-0.88-0.84Beat4.5
    Mar. 31 2023-0.82-0.80-0.74Beat7.7
    

This summary was machine generated May 5 at 11:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

    Recent news on ALX Oncology Holdings

    See all news